BRIDGEWATER - Tharimmune, Inc. (NASDAQ: THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.

The Company will be presenting at the convention and will hold 1x1 meetings with investors and industry leaders.

Event: 2024 BIO International Convention

Date: Monday, June 3, 2024

Time: 1:45 p.m. Pacific Time

Location: Company Presentation Theater 3

To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering system or contact Tirth Patel from LHA Investor Relations at tpatel@lhai.com.

About Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or 'uncontrollable itching' in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets.

Contact:

Email: ir@tharimmune.com

Tirth T. Patel

Email: tpatel@lhai.com

Tel: 212-201-6614

(C) 2024 Electronic News Publishing, source ENP Newswire